{"category":{"kind":"industry","slug":"drug-development","name":"Drug Development","tagline":null,"description":null,"synonyms":[],"target_queries":[],"added_via":"web","added_at":"2026-10-09T13:54:26.869Z","updated_at":"2026-10-09T13:54:26.869Z","example":false,"profile_url":"/industries/drug-development","is_stub":true,"member_count":2,"member_counts":{"company":2}},"members":[{"listing_type":"company","name":"Microbiotica","slug":"microbiotica","tagline":"Clinical-stage precision microbiome medicines for ulcerative colitis and cancer","description":"Microbiotica is a clinical-stage biopharma company near Cambridge, UK, spun out of the Wellcome Sanger Institute in 2016, developing orally dosed live biotherapeutic products. Its genomics-driven platform combines a gut microbiome culture collection, a proprietary reference genome database, bioinformatics and machine learning to identify bacteria associated with favourable clinical trial outcomes. Lead programme MB310, an eight-strain once-daily oral therapy for ulcerative colitis, met its Phase 1b endpoints, and MB097 is being developed with KEYTRUDA for advanced melanoma. On 16 October 2026 Microbiotica announced a £36 million ($48 million) Series C first close led by British Business Bank with Tencent, IP Group, Cambridge Innovation Capital, Flerie Invest and Seventure Partners to take MB310 into Phase 2.","url":"https://microbiotica.com/","is_stealth":false,"normalized_domain":"microbiotica.com","normalized_url_key":"microbiotica.com","parent_slug":null,"parent":null,"type_data":{},"logo":"https://microbiotica.com/wp-content/uploads/2024/06/Microbiotica_Favicon_RGB.png","links":[{"label":"X / Twitter","url":"https://x.com/MicrobioticaLtd","platform":"x"},{"label":"LinkedIn","url":"https://www.linkedin.com/company/microbiotica-limited/","platform":"linkedin"},{"label":"Series C press release","url":"https://microbiotica.com/microbiotica-raises-36-million-48-million-in-series-c-financing-to-advance-pipeline-into-phase-2-clinical-development/","platform":"other"}],"entry_points":[{"kind":"homepage","url":"https://microbiotica.com/","audience":"human","primary":true,"listed_by":"community","on_listing_domain":true},{"kind":"blog","url":"https://microbiotica.com/press-releases/","audience":"human","label":"Press releases","primary":false,"listed_by":"community","on_listing_domain":true},{"kind":"careers","url":"https://microbiotica.com/working-here/","audience":"human","label":"Working here","primary":false,"listed_by":"community","on_listing_domain":true},{"kind":"other","url":"https://microbiotica.com/pipeline/","audience":"human","label":"Pipeline","primary":false,"listed_by":"community","on_listing_domain":true},{"kind":"other","url":"https://microbiotica.com/platform/","audience":"human","label":"Platform","primary":false,"listed_by":"community","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://microbiotica.com/","audience":"human","primary":true,"listed_by":"community","on_listing_domain":true},"agent":null},"founders":[],"media":{"logo_asset_id":"c773eb05-0d47-4a1e-b2ed-7e27bef55b56"},"categories":["Biotech","Microbiome","Drug Development","Healthcare"],"stage":"series-b+","founded_year":null,"location":"Cambridge, United Kingdom","pricing":null,"twitter":"https://x.com/MicrobioticaLtd","github":null,"linkedin":"https://www.linkedin.com/company/microbiotica-limited/","contact_email":null,"added_at":"2026-10-16T22:40:16.996Z","added_via":"web","geo":null,"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-10-16T22:40:16.996Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"biotech","name":"BioTech","note":null,"profile_url":"/industries/biotech"},{"kind":"industry","slug":"drug-development","name":"Drug Development","note":null,"profile_url":"/industries/drug-development"},{"kind":"industry","slug":"healthcare","name":"Healthcare","note":null,"profile_url":"/industries/healthcare"},{"kind":"industry","slug":"microbiome","name":"Microbiome","note":null,"profile_url":"/industries/microbiome"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-10-16T22:40:16.996Z","updated_at":"2026-10-16T22:40:16.996Z"}},{"listing_type":"company","name":"SpectaCell","slug":"spectacell","tagline":"Label-free single-cell analysis platform for immunotherapy potency testing","description":"SpectaCell is a Ghent-based life sciences company spun out of imec, VIB and Ghent University. Its platform combines chip-based imaging with data analysis to track large numbers of individual cells and their interactions directly, at high resolution and over time, without fluorescent labels, so developers can see how a treatment affects individual cells. It targets immunotherapies such as cell therapies (including CAR-T) and T-cell engagers, and is developing a cartridge-based instrument meant to deliver results in hours rather than days, for use from early R&D through manufacturing quality checks. Founded in 2026 by Mathieu Rabaey, Veronique De Vroey, Jan Van de Velde and Tony Montoye (CEO), it launched in October 2026 with €6M in seed financing led by imec.xpand, with PMV's Flanders Future Tech Fund, InnovationQuarter Capital, Qbic and VIB participating (per imec).","url":"https://www.spectacell.com/","is_stealth":false,"normalized_domain":"spectacell.com","normalized_url_key":"spectacell.com","parent_slug":null,"parent":null,"type_data":{},"logo":null,"links":[{"label":"LinkedIn","url":"https://www.linkedin.com/company/spectacell/","platform":"linkedin"},{"label":"imec launch announcement","url":"https://www.imec-int.com/en/press/spectacell-launches-eu6-million-transform-drug-development-and-bring-better-immune-therapies"},{"label":"News","url":"https://www.spectacell.com/news/"}],"entry_points":[{"kind":"homepage","url":"https://www.spectacell.com/","audience":"any","primary":true,"listed_by":"community","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://www.spectacell.com/","audience":"any","primary":true,"listed_by":"community","on_listing_domain":true},"agent":{"kind":"homepage","url":"https://www.spectacell.com/","audience":"any","primary":true,"listed_by":"community","on_listing_domain":true}},"founders":[{"name":"Tony Montoye","role":"Co-founder & CEO","person_slug":"tony-montoye-1eavhwbeplj8q","bio":null,"location":null,"links":[]},{"name":"Mathieu Rabaey","role":"Co-founder","person_slug":"mathieu-rabaey-01u10b5g28wx4","bio":null,"location":null,"links":[]},{"name":"Veronique De Vroey","role":"Co-founder","person_slug":"veronique-de-vroey-3ndwpqi76f1sv","bio":null,"location":null,"links":[]},{"name":"Jan Van de Velde","role":"Co-founder","person_slug":"jan-van-de-velde-2b5hojj1jj034","bio":null,"location":null,"links":[]}],"media":null,"categories":["Biotech","Life Sciences Tools","Cell Therapy","Drug Development"],"stage":"seed","founded_year":null,"location":"Ghent, Belgium","pricing":null,"twitter":null,"github":null,"linkedin":"https://www.linkedin.com/company/spectacell/","contact_email":null,"added_at":"2026-10-09T13:54:26.869Z","added_via":"web","geo":null,"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-10-09T13:54:26.869Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"biotech","name":"BioTech","note":null,"profile_url":"/industries/biotech"},{"kind":"industry","slug":"cell-therapy","name":"Cell Therapy","note":null,"profile_url":"/industries/cell-therapy"},{"kind":"industry","slug":"drug-development","name":"Drug Development","note":null,"profile_url":"/industries/drug-development"},{"kind":"industry","slug":"life-sciences-tools","name":"Life Sciences Tools","note":null,"profile_url":"/industries/life-sciences-tools"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-10-09T13:54:26.869Z","updated_at":"2026-10-09T13:54:26.869Z"}}],"total":2,"limit":50,"offset":0}